First age group treated in paediatric diabetes study with ProTrans

April 7, 2022

First age group treated in paediatric diabetes study with ProTrans

NextCell Pharma AB("NextCell") today announces that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.

 

The first part of the study is a safety part (phase Ib) where all patients are treated at Uppsala University Hospital. The Safety Committee consists of Chairman Professor Ulf Smith, Sahlgrenska Hospital and Professor Mikael Rydén, Karolinska University Hospital and Professor Anders Fasth, Queen Silvia Children's Hospital. They will evaluate whether it is safe to proceed to the phase II part of the study, based on 3 months of follow-up of the total of six children.

In the second part of the study, patients are randomized to ProTrans or placebo (1:1). First,30 patients in the 12-21 age group will be treated and based on safety evaluation after six months, 30 patients in the 7-11 age group will also be treated.

The principal investigator is Professor Per-Ola Carlsson, Uppsala University and Uppsala University Hospital with co-investigators Professor Helena Elding Larsson, Skåne University Hospital and Professor Johnny Ludvigsson, Linköping University Hospital. The second part is randomised and placebo-controlled (phaseII) and a total of 60 children and adolescents with type 1 diabetes should be treated, of which 30 with ProTrans and 30 with placebo. Recruitment will take place at the three participating hospitals in Uppsala, Linköping and Malmö.

"Our assessment is that we will be able to include all patients in the safety part during the spring and hopefully be able to start recruiting patients to the second part after the summer," says Professor Carlsson.

Akademiska sjukhuset is a sponsor of the study, which is funded with research grants. NextCell is contributing ProTrans and placebo in the study. In addition, the company will support the trial with logistics, documentation and expertise.

The full name of the study is: “A Double-blinded, Randomized, Parallel, Placebo-controlled trial of Wharton´s Jelly-derived Allogeneic Mesenchymal Stromal Cells to treat Type I Diabetes in Children and Adolescents” (EudraCT2020-004520-42).

 

For more information about NextCell PharmaAB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel:08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

 

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

 

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

 

 

 

Download attachmentRead full press release on Cision (external link)
2025-01-30
NextCell Pharma publish Interim Report 1 2024/2025
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Read moreRead more
2024-12-17
Long-term Effects with Repeated ProTrans Treatment After 6 Years
NextCell Pharma AB reports new results from the ProTrans-Repeat study, where type 1 diabetes patients have been followed for 5 years after receiving two doses of the stromal cell product ProTrans, in total 6 years after the first infusion. The results show that two out of three patients in the high-dose group increased their insulin production by 23% and 34% respectively.
Read moreRead more
2024-12-05
NextCell Pharma changes Certified Adviser to Redeye AB
NextCell Pharma has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on January 1, 2025.
Read moreRead more
2024-11-25
QVance’s Partnerships Driving Innovation in Advanced Therapies
NextCell Pharma AB*, parent company of QVance, proudly supports QVance’s newly announced partnership with Royale International. This collaboration, which combines Royale International’s global expertise in logistics with QVance’s innovative quality control solutions, strengthens the supply chain for cell and gene therapies across Europe.
Read moreRead more
2024-11-18
QVance Announces Partnership
NextCell Pharma AB* comments on its subsidiary QVance’s partnership with bioMérieux Sweden AB, which aims to strengthen quality control analytics for cell and gene therapy products in the Nordic region. The collaboration will enhance QVance’s capacity to provide microbiological testing for advanced therapies.
Read moreRead more
2024-11-08
QVance AB Publishes Article on Particulates in Cell and Gene Therapy Products in Collaboration with ISCT
NextCell Pharma AB* announces that its subsidiary, QVance AB, has published an article in collaboration with the International Society of Cell and Gene Therapy (ISCT). The article, authored by Dr. Lindsay Davies, CSO at NextCell and co-founder of QVance, was published in Cytotherapy and is based on a global survey examining knowledge on particulates in cell and gene therapy (CGT) products.
Read moreRead more
2024-11-04
NextCell Pharma AB participates in BIO-Europe 2024 and welcomes a visit from Minister Ebba Busch
NextCell Pharma AB* proudly announces its participation in BIO-Europe 2024, one of Europe’s most significant partnering conferences in biotechnology and pharmaceutical development. The event will be held at Stockholmsmässan from November 4-6, and is expected to gather over 5,000 leading professionals from around the world.
Read moreRead more
2024-10-24
NextCell publishes its Year-End Report 2023/2024
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2023 – August 31, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more